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Abstract
Tuberculosis and sarcoidosis are inflammatory diseases characterized by
granulomas that may occur in any organ but are often found in the lung. The
panoply of classical human leukocyte antigen (HLA) alleles associated with
occurrence and/or severity of both diseases varies considerably across studies.
This heterogeneity of results, due to variation in factors like ancestry and
disease subphenotype, as well as the use of simple modeling strategies to
elucidate likely complex relationships, has made conclusions about underlying
commonalities difficult. Here we perform HLA association analyses in
individuals of African ancestry, using a greater resolution to include
subphenotypes of disease and employing more comprehensive analytical
techniques. Using a novel application of nearest‐neighbor feature selection to
score allelic importance, we investigated HLA allele association with
Mycobacterium tuberculosis exposure outcomes in the first analysis of both
latent Mycobacterium tuberculosis infection and active disease compared with
those who, despite long‐term exposure to active index cases, have neither
positive diagnostic tests nor display clinical symptoms. We also compared
persistent to resolved sarcoidosis. This led to the identification of novel HLA
associations and evidence of main effects and interaction effects. We found
strikingly similar main effects and interaction effects at HLA‐DRB1, ‐DQB1,
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and ‐DPB1 in those resistant to tuberculosis (either latent or active) and
persistent sarcoidosis.
KEYWORDS

epistasis, HLA, Mycobacterium tuberculosis, nearest‐neighbor feature selection, resistance to
infection, sarcoidosis
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INTRODUCTION

Active tuberculosis disease is consistently among the
most deadly infectious diseases each year and the
incidence of disease in African countries is among the
highest worldwide (Global Tuberculosis Report, 2020).
Tuberculosis disease is caused by Mycobacterium tuberculosis (Mtb) infection and is characterized by caseating
granulomas. Although most instances of Mtb exposure
result in latent Mtb infection or clinically active disease,
some individuals, called “Resisters,” maintain negative
diagnostic tests for Mtb infection over many years of
follow‐up despite long‐term exposure to index cases with
active disease (Stein et al., 2018, 2019). Sarcoidosis, also a
granulomatous disease, is characterized by noncaseating
granulomas and thought to be the host immune response
to unknown antigen(s) (Iannuzzi, 2007) in individuals
with a genetic predisposition. Phenotypes in sarcoidosis
are also highly heterogeneous, ranging from complete
resolution, with or without medical intervention, to
persistent and even fibrotic disease (Baughman
et al., 2009). In the United States, the incidence of
sarcoidosis is the highest (Mirsaeidi et al., 2015; Rybicki
et al., 1997) and the clinical manifestations are more
severe (Israel et al., 1986; Mirsaeidi et al., 2015) in
African Americans as compared with other ancestral
groups. Myriad infectious agents have been examined for
a potential role in causing sarcoidosis (Esteves et al., 2016;
Gupta et al., 2007; Zhou et al., 2013), with Mtb being one
of the most extensively studied, however, the etiology of
sarcoidosis remains elusive. Regardless, by studying
them jointly, much can be learned about both diseases
due to their highly similar clinical manifestations.
Variants within the human leukocyte antigen (HLA)
genomic region are associated with both active tuberculosis disease (Tong et al., 2015; Yang et al., 2016) and
sarcoidosis (Fingerlin et al., 2015). The class II HLA loci:
DRB1, DQB1, and DPB1 are of particular concern due to
their central role in antigen recognition and presentation
to helper T cells via antigen‐presenting cells, which is the
initial mechanism leading to granuloma formation and
persistence that characterizes both tuberculosis disease
and sarcoidosis (Grunewald et al., 2019). A recent review
summarizes and compares HLA associations in the two

diseases (Malkova et al., 2020), making two broad
conclusions: (1) DRB1*03, *07, and *15 predispose for
sarcoidosis and protect against tuberculosis, and (2)
DRB1*04 predisposes for tuberculosis disease and protects against sarcoidosis. These comparisons are representative of one major limitation; to date, there are no
comparisons of HLA associations in Mtb exposure
outcomes and sarcoidosis that include subphenotypes
of disease, such as latent Mtb infection or persistent
sarcoidosis. Further, no studies report HLA associations
with “Resisters” (Stein et al., 2018, 2019). Discovering
associations of class II HLA loci to all outcomes related to
Mtb exposure and sarcoidosis could provide insight into
potential mechanisms for long‐term resistance against
conversion to positive diagnostic tests.
Finally, the few existing HLA association studies in
individuals of African ancestry indicate considerable
deviation from the effects in other groups, the majority
of which were identified in individuals of European or
Asian populations (Fingerlin et al., 2015; Malkova
et al., 2020; Tong et al., 2015; Yang et al., 2016). This
study probed for HLA associations with outcomes of Mtb
exposure in individuals from a densely populated region
of Kampala, Uganda (Mchenry et al., 2021; Stein
et al., 2018, 2019), whereas associations with sarcoidosis
outcomes were assessed in Americans of African ancestry
(ACCESS Research Group, 1999; Baughman et al., 2001;
Rybicki et al., 2007). Uganda is a high‐burden country for
tuberculosis disease, with a recently estimated incidence
of 196 per 100,000 (Global Tuberculosis Report, 2020);
this is almost surely higher in the populous region of
Kampala, with a recent estimate of 740 per 100,000 (Stein
et al., 2018). In the United States, the incidence of
sarcoidosis in African Americans is recently estimated at
17.8 per 100,000; this incidence is more than double that
of European Americans (8.1 per 100,000), more than four
times that of Hispanics (4.3 per 100,000), and more than
five times that of Asians (3.2 per 100,000) (Baughman
et al., 2016).
Using a method called Nearest‐neighbor Projected‐
Distance Regression (NPDR) that is designed for detecting complex associations in high‐dimensional bioinformatic data (Le et al., 2020), we examined high‐resolution
HLA‐DRB1, ‐DQB1, and ‐DPB1 alleles across distinct
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subphenotypes of Mtb exposure and sarcoidosis in
individuals of African ancestry, seeking to identify novel
main effect and epistatic associations both unique to and
common across diseases. These findings can help guide
mechanistic hypotheses explaining the highly variable
responses to these two clinically similar but etiologically
distinct granulomatous disorders.

2 |

MATERIALS A ND METHODS

2.1

| Subjects and phenotype definitions

3

with latent Mtb infection and Resisters in the long‐term
follow‐up study (Stein et al., 2019) were typed from a
combination of the Illumina MEGAEX and Illumina
Omni5 chips. Genome‐wide genotyping for our sarcoidosis outcome data is reported in another GWA study
(Adrianto et al., 2012). Genotyping for sarcoidosis cases
and healthy controls was performed using the Illumina
HumanOmni1‐Quad chip (Adrianto et al., 2012).

2.3 | Identification of HLA alleles
Our Mtb exposure outcome cohort derived from individuals participating in a household‐contact study in an
urban region of Kampala, Uganda (Mchenry et al., 2021;
Stein et al., 2018, 2019). Individuals living with a
confirmed, culture positive, clinically active tuberculosis
case at enrollment were screened with tuberculin skin
tests (TSTs) performed every 3 months for the first 2
years to identify individuals with latent Mtb infection and
“Resisters” (Stein et al., 2018). Latent Mtb infection was
defined as individuals who never converted to active
disease in spite of positive TSTs, while Resisters were
individuals who consistently tested negative by both
TSTs and interferon‐gamma release assays (IGRA) over
an average of 11 years (Stein et al., 2018, 2019). This
study focuses on three subphenotypes of Mtb exposure,
including active tuberculosis disease (n = 202), latent Mtb
infection (n = 228), and Resisters (n = 87). Approximately 64% of the individuals were vaccinated with the
bacille Calmette‐Guérin (BCG) vaccine, and the proportions of vaccinated individuals did not differ between
groups (Stein et al., 2018, 2019). Our sarcoidosis data
derive from family and case–control studies of African
American individuals with sarcoidosis (n = 664), confirmed by the presence of granulomas in biopsy tissue
and the absence of mycobacterial or fungal infection. The
healthy controls were family members and unrelated
individuals matched to the cases for age, sex, and race
(n = 518) (ACCESS Research Group, 1999; Baughman
et al., 2001; Rybicki et al., 2007). Persistent (n = 343) or
resolved (n = 134) sarcoidosis status was determined by
radiographic evidence of continued lung involvement at
2‐year follow‐up.

2.2

| Genotyping

Genome‐wide genotyping for the Mtb exposure outcome
cohort is reported in a genome‐wide association (GWA)
study (Mchenry et al., 2021). Briefly, active cases from
the original 2‐year study (Stein et al., 2018) and those

In our Mtb exposure data set, HLA‐DRB1, ‐DQB1, and
‐DPB1 alleles were identified via deep sequencing for 37
individuals (Wang et al., 2012), while those for the
remaining 728 individuals were imputed with HLA
Genotype Imputation with Attribute Bagging (HIBAG)
(Zheng et al., 2014) from genome‐wide single‐nucleotide
polymorphism (SNP) data mentioned above. In our
sarcoidosis data set, HLA‐DRB1, ‐DQB1, and ‐DPB1
alleles were identified via PCR amplification and
hybridization with sequence‐specific oligonucleotide
(PCR‐SSO) probes in 325 individuals who also had
genome‐wide
genotyping
(ACCESS
Research
Group, 1999; Rossman et al., 2003). These 325 individuals
were used as reference for imputing alleles in the
remaining 857 individuals with HIBAG using the
genome‐wide SNP data mentioned above. Accuracy of
the HIBAG method specific to our sarcoidosis data set
has previously been reported (Levin et al., 2014, 2015).
For our Mtb exposure data set, we implemented HIBAG
using prebuilt classifiers with published parameter
estimates, trained on samples of African ancestry (Zheng
et al., 2014), to predict HLA‐types from genome‐wide
genotypes (Mchenry et al., 2021; Stein et al., 2018, 2019).
Before imputation, we filtered out all SNPs with missing
call rate in excess of 0.01 and those with minor allele
frequency less than 0.05.

2.4 | HLA allelic importance
To identify the HLA‐DRB1, ‐DQB1, and ‐DPB1 alleles
that best delineate disease groups, we applied a machine
learning algorithm that scores the importance of a
predictor variable in the presence of covariates
(Nearest‐neighbor Projected‐Distance Regression, NPDR)
(Le et al., 2020). Importance scores were adjusted for
background relatedness and imputation uncertainty. For
background relatedness adjustment, we used the first 10
principal components of the genetic relationship matrix
for each cohort. We adjusted for imputation uncertainty
using HIBAG posterior probabilities, assigning all
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unimputed HLA alleles a probability of 1. HLA alleles
with counts less than five in both phenotype groups for a
given outcome were excluded before determining importance scores. NPDR p‐values were adjusted for multiple
testing by Bonferroni correction.
Nearest‐neighbor feature selection is usually applied
with only one neighborhood method (Urbanowicz
et al., 2018), however using simulated data it has been
shown that the ability of a nearest‐neighbor feature
selection method to detect main effects and/or interaction effects changes as a function of neighborhood size
(Dawkins et al., 2021; Mckinney et al., 2013; Urbanowicz
et al., 2018). Here NPDR importance scores were
calculated using three different neighborhood methods:
(1) an adaptive‐radius method (Urbanowicz et al., 2018)
that allows each instance (or sample) to have its own
neighborhood radius, (2) a fixed‐k method (Dawkins
et al., 2021; Le et al., 2020) that takes into account
moments of the sample distance distribution, and (3) a
variable‐wise optimized fixed‐k method (Mckinney
et al., 2013) that allows each allele to have its own
optimized neighborhood size (or fixed‐k). Only those
alleles with statistically significant adjusted NPDR
p‐values for all three methods (termed here as
“consensus positives”) were considered relevant for
classifying a particular outcome. The top 15 associations,
ranked according to NPDR consensus importance, are
described below and the remainder are included in
Supporting Information Materials (Supporting Information: Figure S1).

2.5

| Simulated data

We used simulated case–control data to compare the
performance of our NPDR consensus method to each of
the three input methods, as well as univariate logistic
regression (Supporting Information: Figure S2). Main
effect and interaction effect simulations were generated
using the createSimulation() function from a software
package called private Evaporative Cooling (privateEC)
(Le et al., 2017). Main effect simulations were based on
an approach that uses a linear model to generate data
characteristic of bioinformatic applications (Leek &
Storey, 2007). Interaction effect simulations were based
on a method that generates differential correlation from a
random network with Erdős‐Rényi degree distribution
(Lareau et al., 2015). We generated 30 replicate simulations for assessing algorithm performance in detecting
main effects and interaction effects, respectively. Each
simulated data set had m = 50 samples and p = 1000
features with 10% functional (i.e., relevant to the
outcome). For main effect simulations, we set the effect
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size parameter (bias) of createSimulation() to 0.8 which
corresponds to the statistical power of about 40% (Le
et al., 2017). For interaction effects, bias was set to 0.4
and is inversely proportional to the level of correlation
between functional features (i.e., features involved in
interaction effects relevant to the outcome) in the
“control” group. In the “case” group, correlation between
functional features is disrupted through random permutation (Lareau et al., 2015).
The Area Under the Precision‐Recall Curve
(AUPRC), precision, and recall were chosen as performance metrics for comparing different feature selection
algorithms. To calculate each performance metric, we
defined “positives” as features that were functionally
related (i.e., relevant) to the binary outcome. Thus, a true
positive (TP) is a relevant feature that was detected by a
given feature selection algorithm. AUPRC was derived by
calculated precision and recall across a grid of increasing
feature selection thresholds. We also calculated precision
and recall using a p‐value threshold of nominal significance (P < 0.05) for each feature selection algorithm. We
found that NPDR consensus positives had higher
precision overall than NPDR positives among the three
individual neighborhood methods, respectively (Supporting Information: Figure S2A). We also compared
performance between our NPDR consensus approach
and univariate logistic regression with respect to detecting simulated main effects and interaction effects
(Supporting Information: Figure S2B). While univariate
logistic regression had an advantage in detecting main
effects, it completely failed in detecting interaction effects
(Supporting Information: Figure S2B). To the contrary,
our NPDR consensus approach allowed for the detection
of both main effects and interaction effects, significantly
improving overall detection of functional features (Supporting Information: Figure S2B).

2.6 | Regression analysis
Only those outcomes having at least one allele with
statistically significant NPDR importance were included
in follow‐up regression analysis. We used a generalized
linear model to determine odds ratios for each HLA allele
for which NPDR importance was statistically significant
(Supporting Information: Tables S1–S2). For each HLA
allele detected by NPDR in at least one outcome of Mtb
exposure or sarcoidosis, respectively, we calculated odds
ratios for all possible two‐way interactions for which
there was sufficient data, excluding combinations of
alleles that were observed in fewer than five individuals
(Supporting Information: Tables S3–S4). We report only
nominally significant (P < 0.05) interactions involving at
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least one allele detected by NPDR, possibly including
alleles for which NPDR importance was not statistically
significant; for visualization purposes only, odds ratios
were calculated in this latter scenario. Each model
included the first 10 principal components of the genetic
relationship matrix and HIBAG posterior probabilities
for the corresponding HLA loci. We used a dominant
model assumption for all main effect and interaction
effect odds ratios. Testing for the presence of interaction
was done using a likelihood ratio test. We also calculated
the standardized difference of proportions for each HLA
allele to illustrate NPDR allelic importance and the
corresponding unadjusted directionality in disease risk.
We visualized main effects and interaction effects in a
regression‐based Genetic Association Interaction Network (reGAIN) (Lareau et al., 2015; Mckinney et al., 2009;
Pandey et al., 2012), showing pairwise interactions
reaching nominal significance and corresponding main
effects in the absence of any interaction term (Supporting
Information: Figures S3–S7).
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RESUL TS

To determine which HLA alleles contributed most
significantly to outcomes in Mtb exposure and sarcoidosis, we used NPDR to calculate allelic importance scores
(Figure 1a–e). Larger importance scores correspond to
stronger relationships between alleles and the log‐odds of
two individuals having a different phenotype. Thus,
alleles with a higher rank of importance can be thought
of as being better for classification of a given outcome, or
subphenotype comparison, regardless of directionality of
disease risk. Main effects (Supporting Information:
Tables S1–S2) and interaction effects (Supporting Information: Tables S3–S4) were determined to annotate
allelic importance with directionality for odds of disease.

3.1 | HLA‐DRB1, ‐DQB1, and ‐DPB1
associations in Mtb exposure outcomes
There were several alleles important for distinguishing
those with active disease (Figure 1a), latent Mtb infection
(Figure 1b), and the combined group of active disease or
latent Mtb infection (Figure 1c) from Resisters. We found
no alleles distinguishing those with active disease from
those with latent Mtb infection, thus this contrast was
excluded from further regression analysis. When comparing the combined group of active disease or latent Mtb
infection to Resisters, two alleles were associated with
decreased risk: DQB1*02:02 and DPB1*105:01 (Supporting Information: Table S1). Most of the HLA alleles with

5

significant importance were involved in pairwise interactions (Supporting Information: Table S3), not main
effects. DPB1*01:01 was ranked among the highest in
terms of importance for Mtb exposure outcomes
(Figure 1a–c), and coupled with DPB1*04:01, had the
strongest interaction associated with increased risk when
comparing those with latent Mtb infection to Resisters
(Supporting Information: Table S3). This same effect was
observed when comparing the combined group of active
disease and latent Mtb infection to Resisters (Supporting
Information: Table S3). DRB1*03:02 was also among
those with the highest importance scores, and, coupled
with DQB1*02:01, had the strongest interaction associated with decreased risk when comparing the combined
group of active disease and latent Mtb infection to
Resisters (Supporting Information: Table S3). There were
several other nominally significant ( p < 0.05) interactions, predominantly associated with decreased risk
(Supporting Information: Table S3).

3.2 | HLA‐DRB1, ‐DQB1, and ‐DPB1
associations in sarcoidosis outcomes
We confirmed several previously reported associations
for our sarcoidosis cohort (Iannuzzi et al., 2003; Levin
et al., 2015). These included an association with
increased risk of sarcoidosis: DRB1*03:02 (Supporting
Information: Table S2). Also among these were associations with decreased risk of sarcoidosis onset:
DRB1*01:01, DRB1*03:01, DRB1*09:01, DRB1*13:04,
and DQB1*02:01 (Supporting Information: Table S2).
Finally, we confirmed an association with decreased risk
of developing persistent disease for DRB1*03:02 (Supporting Information: Table S2). In addition to confirming
known associations, we found several novel associations
with sarcoidosis outcomes for this cohort (Figure 1d–e).
Among these, DRB1*11:02 was associated with decreased
risk of sarcoidosis onset, while DPB1*40:01 was associated with decreased risk for persistent sarcoidosis
(Supporting Information: Table S2). Most of the HLA
alleles with significant importance scores were involved
in pairwise interactions (Supporting Information:
Table S4). DRB1*04:04 was ranked among the highest
in terms of importance for the comparison of sarcoidosis
cases with healthy controls; in combination with
DPB1*03:01, it had one of the strongest interaction
effects associated with increased risk of sarcoidosis onset
(Supporting Information: Table S4). Other highly ranked
alleles for the comparison of sarcoidosis cases and
healthy controls had nominally significant ( p < 0.05)
interactions, predominantly associated with increased
risk of onset (Supporting Information: Table S4).
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DRB1*12:01 and DPB1*17:01 were ranked among the
highest in terms of importance for the comparison of
persistent and resolved sarcoidosis; interactions between
DRB1*12:01 and DRB1*11:01 and between DPB1*17:01
and DRB1*03:01 had the strongest associations with
decreased risk for persistent disease (Supporting Information: Table S4). DRB1*01:02 was also ranked among
the highest for the comparison of persistent and resolved
sarcoidosis, and coupled with DPB1*01:01, had the
strongest interaction associated with increased risk for
persistent disease (Supporting Information: Table S4).
There were several other nominally significant interactions ( p < 0.05) involving highly ranked alleles for the
comparison of persistent and resolved sarcoidosis as well
(Supporting Information: Table S4).

3.3 | Shared HLA importance and
directionality between Resister phenotype
of Mtb exposure and resolved sarcoidosis
Alleles that were important for distinguishing those
with active tuberculosis disease or latent Mtb infection
from Resisters (Figure 1a–c), tended to also be important for distinguishing persistent from resolved sarcoidosis (Figure 1e); there was less overlap with the
comparison of sarcoidosis cases versus controls
(Figure 1d). Overall, there were six alleles of overlapping importance between Mtb exposure and sarcoidosis outcomes (Figure 1f): DRB1*01:02, DRB1*03:02,
DRB1*13:02, DQB1*04:02, DQB1*06:09, and DPB1*
15:01. With one exception, these alleles were found in
higher proportion among Resisters and those with
resolved sarcoidosis, relative to their counterpart
comparison phenotypes. On the contrary, two of these
resistance‐associated alleles were more frequent in
sarcoidosis cases than healthy controls: DRB1*03:02
and DQB1*04:02; this was also true after covariate
adjustment (Supporting Information: Table S2).

7

3.4 | Interaction networks reveal
high‐order similarities between Resister
phenotype of Mtb exposure and resolved
sarcoidosis
As mentioned above, there were many nominally significant
interaction effects involving alleles with significant importance scores for outcomes of Mtb exposure (Supporting
Information: Table S3) and sarcoidosis (Supporting Information: Table S4). To make a comprehensive, high‐order
comparison of the interactions between different outcomes,
we created regression‐based Genetic Association Interaction
Networks (reGAIN) for each outcome of Mtb exposure
(Supporting Information: Figures S3–S5) and sarcoidosis
(Supporting Information: Figures S6–S7). Each node of a
given network represents a single HLA allele and the edges
(or connections) between nodes represent interactions,
which we only allowed if the interaction was at least
nominally ( p < 0.05) significant. By comparing reGAINs
involving HLA alleles with significant importance scores, we
found many similar interaction subnetworks between
outcomes of Mtb exposure and sarcoidosis (Figure 2). Four
subnetworks were highly concordant for two outcomes in
particular: (1) persistent versus resolved sarcoidosis and (2)
the combined active tuberculosis disease or latent Mtb
infection versus Resister. In all but the comparison of active
tuberculosis disease versus Resister, we found interactions
between DPB1*02:01 and DQB1*06, primarily DQB1*06:09.
Finally, we found that an interaction between DPB1*01:01
and DQB1*03 was shared in the comparison of sarcoidosis
case versus control, as well as comparing active tuberculosis
disease or latent Mtb infection to Resister.

4 | DISCUSSION
In this study, we compared HLA associations with
outcomes of Mtb exposure and sarcoidosis in individuals
of African ancestry. We conducted the first HLA

F I G U R E 1 HLA allelic importance in Mtb exposure and sarcoidosis outcomes. (a–e) Top 15 HLA alleles, ranked in decreasing
magnitude of NPDR standardized regression coefficient—that is, variable importance, are shown for each outcome. Mtb exposure outcomes:
(a) Active (n = 202) versus Resister (n = 87), (b) Latent (n = 228) versus Resister (n = 87), (c) Active + Latent (n = 430) versus Resister
(n = 87). Sarcoidosis outcomes: (d) Sarcoidosis (n = 664) versus control (n = 518) and (e) Persistent (n = 343) versus Resolved (n = 134).
Vertical‐dashed line is the standard normal quantile corresponding to the NPDR p‐value significance threshold for each respective outcome
(a–e). HLA alleles with significant adjusted NPDR p‐values in at least one Mtb exposure and sarcoidosis outcome are highlighted in green
(a–e). For these overlapping HLA alleles, the standardized difference of proportion and ‐log10 NPDR p‐value are shown (f). Arrow length is
proportional to the magnitude difference in allele proportions between phenotype groups. Arrows pointing left correspond to alleles more
common in the “control” group, while arrows pointing right correspond to alleles more common in the “case” group. Point sizes are
proportional to the ‐log10 NPDR p‐value. Alleles with nominally significant ( p < 0.05) regression coefficients are labeled: main effects (*)
and interaction effects (†). Allele frequencies are provided in parentheses for significant alleles (case frequency, control frequency). HLA,
human leukocyte antigen; NPDR, Nearest‐neighbor Projected‐Distance Regression.
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F I G U R E 2 Interaction subnetwork similarities for Mtb exposure and sarcoidosis outcomes. Subnetworks present were extracted from
reGAINs for each Mtb exposure (Supporting Information: Figures S3–S5) and sarcoidosis (Supporting Information: Figures S6–S7) outcome.
Each subnetwork includes only those interactions that were nominally significant ( p < 0.05) and involving alleles detected by NPDR
(Supporting Information: Tables S3–S4). Node color corresponds to the adjusted odds ratio in the absence of nonadditive effects, indicating
whether the allelic odds ratio was protective (green, 0 < OR < 1) or predisposing (red, OR > 1) for a given disease subphenotype. Edge color
corresponds to the interaction effect odds ratio for a given pair of adjacent alleles, similarly indicating whether the interaction effect odds
ratio was protective (green, 0 < OR < 1) or predisposing (red, OR > 1) for a given disease subphenotype. Node size and edge width not drawn
to scale. NPDR, Nearest‐neighbor Projected‐Distance Regression.

association analysis to include individuals with consistently negative diagnostic tests for Mtb infection,
despite long‐term exposure to index cases with active
disease. This led to the discovery of several HLA‐DRB1,
‐DQB1, and ‐DPB1 alleles distinguishing this resistant
phenotype from both active disease and latent Mtb
infection. We also found novel allelic associations in
HLA‐DRB1, ‐DQB1, and ‐DPB1 distinguishing sarcoidosis cases from healthy controls, as well as persistent
from resolved sarcoidosis. Although a subset of the
associations detected with nearest‐neighbor feature
selection could be attributed to main effects, most were
explained only by pairwise interactions. Comparing
HLA associations between outcomes of Mtb exposure
and sarcoidosis, there was striking similarity; HLA
alleles important for distinguishing subphenotypes of
Mtb exposure from resisters tend to also distinguish
persistent and resolved sarcoidosis. These similarities
extended beyond just allelic importance. We observed
parallels in directionality of disease risk, both for main
effects and interaction effects, revealing a common

interaction network architecture for these two granulomatous disorders.
One of the more striking findings of our study is that
we found no association with HLA‐DRB1, ‐DQB1, or
‐DPB1 when comparing individuals with latent Mtb
infection to those with active disease. The comparison of
active disease and latent Mtb infection is relatively rare
(Oliveira‐Cortez et al., 2016); control groups are often
heterogeneous and consisting of individuals with positive
and negative TSTs, respectively (Duarte et al., 2011;
Magira et al., 2012), which are known (along with
interferon‐γ release assays) to poorly distinguish between
latent Mtb infection and active disease (Abubakar
et al., 2018). While no specific associations were found
in our study, other HLA‐dependent genetic or immunological mechanisms may be at play. For example, the
expression of HLA‐DR on Mtb‐specific IFN‐γ + TNF‐α +
cells is reportedly higher in individuals with active
disease compared with those with latent Mtb infection
(Luo et al., 2021). Future work examining activated
cellular immune responses to Mtb or cell‐type‐specific
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expression may gain additional mechanistic insight into
the role of specific HLA genotypes.
Interestingly, most of the HLA associations that were
common to Mtb exposure outcomes and sarcoidosis
tended to be those that were previously reported. For
example, DRB1*03:01 and *03:02 as well as DQB1*02:01
are strongly associated with sarcoidosis across multiple
ancestries (Fingerlin et al., 2015; Levin et al., 2015) and
DQB1*04:02 has been shown to be protective against
active tuberculosis across multiple ancestries (Oliveira‐
Cortez et al., 2016). However, it is important to note that
our use of a more inclusive approach allowed for the
identification of HLA alleles involved in pairwise
interactions, which are important in delineating outcomes of Mtb exposure and sarcoidosis and would not
have been found using traditional approaches. For
example, DQB1*04:02 has not previously been associated
with sarcoidosis, but here, we show it significantly
interacts with DRB1*03:02 to protect against persistent
sarcoidosis. Evidence for more complex effects involving
DRB1*03:02 and DQB1*04:02 also exists outside the
context of sarcoidosis, with the DRB1*03:02‐
DQA1*04:01‐DQB1*04:02 haplotype reported to be
highly protective against Type 1 diabetes in African
Americans (Howson et al., 2013). Similarly, DQB1*04:02
was shown here to interact with DQB1*02:01 and
associate with resistance against active tuberculosis, but
to predispose to disease in combination with
DRB1*11:01. Finally, we found DPB1*02:01 and *04:01
involved in nearly identical interaction subnetworks for
Mtb exposure resisters and resolved sarcoidosis. These
HLA alleles have strong effects in chronic beryllium
disease (Mccanlies et al., 2003), a differential diagnosis of
sarcoidosis.
Finally, while mechanistic studies of these HLA
alleles are outside of the scope of this article, it is
important to note that in vitro and in vivo effects may not
be tied directly to the role of HLA‐DRB1, ‐DQB1, or
‐DPB1 in antigen presentation. Previous studies have
suggested both a unique innate and adaptive immune
response to Mtb in Resisters (Seshadri et al., 2017) via
peripheral monocytes differentially activating pathways
controlled by histone deacetylase. This pathway, along
with IFN‐γ signaling, is known to be aberrant in
sarcoidosis, via dysregulation of the enzyme 1α‐
hydroxylase and the systemic excess of 1,25(OH)2D3
and hypercalcemia seen in sarcoidosis (Overbergh
et al., 2006). In addition, a previous study of this exact
Mtb exposure cohort found a distinct immunological
profile of Resisters characterized by immunoglobulin M
(IgM), class‐switched IgG antibody responses, and non‐
IFN‐γ T‐cell responses to the Mtb‐specific proteins
ESAT6 and CFP10, confirming exposure without
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pathology (Lu et al., 2019). Th17 cells from sarcoidosis
patients also show reduced IFN‐γ responses to ESAT6
(Richmond et al., 2013). These studies suggest resistance
to persistent forms of sarcoidosis or Mtb infection may be
controlled by multiple shared pathways, including IFN‐γ
responses.
The main objective of this study was to compare class
II HLA associations with outcomes of Mtb exposure and
sarcoidosis, including subphenotypes, to learn more
about both diseases. We showed that by using a tool
free of model specification, we could confirm previously
reported HLA associations, including DRB1*01:01,
*03:01, *03:02, *09:01, *13:04, and DQB1*02:01, and
identify novel associations. The overlapping genetic
associations between resistant phenotypes of Mtb exposure and sarcoidosis suggest commonalities in
immune‐mediated resistance to both diseases and
suggest etiological and mechanistic insight to be gained
by their joint examination, as well as the importance of
examining both single‐allele and more complex
associations.
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